News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Peptech Limited Successfully Completes Phase I Trial for PN0621
October 29, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
29 October 2007 Sydney, Australia: Biopharmaceutical company, Peptech Limited (ASX: PTD, AIM: PTDx) today announced the completion of the Phase I trial of its lead compound for rheumatoid arthritis PN0621.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
Australia
MORE ON THIS TOPIC
Insights
Biotech’s New Cycle, JPM Deal Hype and Where Alpha Still Hides
January 29, 2026
·
1 min read
·
Jennifer Smith-Parker
gene therapy
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
January 28, 2026
·
4 min read
·
Heather McKenzie
Cancer
Cardiff Craters Amid Executive Exits, Mixed Mid-Stage Data
January 28, 2026
·
2 min read
·
Tristan Manalac
Podcast
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
January 28, 2026
·
1 min read
·
Heather McKenzie
